International Journal of Hematology-Oncology and Stem Cell Research
Volume:7 Issue: 1, Jan 2013

Lymphomas are a group of malignancies affecting B, T and NK cells. COX-2 enzyme is one of the known inflammatory factors which increase in the inflammation process. Increase in COX-2 expression inhibits apoptosis and increases tumor cells invasion and angiogenesis. Increase in the COX-2 gene expression is seen in a group of cancers. Specific COX-2 inhibition also can be beneficial in some cancers through apoptosis stimulation. In a descriptive-analytic study, COX-2 expression degree was evaluated in patients with non-Hodgkin lymphoma. Patients’ cases were used to study the following variables: gender, age, lymphoma type, and stage of the disease, the degree of the disease, existence of B symptom, extranodal involvement, and response to treatment, death, and LDH levels. Paraffin-embedded tissue blocks from 153 cases of non-Hodgkin and Hodgkin lymphoma were selected for immunohistochemical staining for COX-2 expression. COX-2 level were reported positive in four (4.7%), patients with non-Hodgkin lymphoma and four (5.7%), patients with Hodgkin lymphoma. During the seven year follow-up, 15 patients were suffering from the disease relapse and 9 patients died during this period. There were no significant relation between others quantitative and qualitative variables and COX-2 expression. Also, There was no relation between COX-2 and type of lymphoma (P=0.476). According to our results, there was no relation between cox-2 expression and type of lymphoma. We recommend more patients are needed for more assess cox-2 expression. On the other hand, in our study most of the patients had Azari Race, may be, have an effect in our results

Breast cancers are divided into at least 4 sub Types on the Basis of gene expression profiles and expression of receptors as measured by IHC (Immunohistochemical). Triple negative breast cancer (TNBC) is more chemosensitive yet, it is much harder to detect than other sub types. At present lack of highly effective therapeutic targets for TNBC, Leaves standard chemotherapy, as the only medical treatment but it is not remarkably efficient. CMF (cyclophosphamide-MTX-5-fu) chemotherapy is effective in some sub types of TNBC.Patients and A Total of 40 patients with TNBC who had undergone surgical resection because of primary Invasive Breast cancer were studied from 2009 to 2011. Twenty patients in treatment group received four cycles of modified CMF after standard chemotherapy and 20 patients in group control Received standard chemotherapy (Antracycline / Taxane), Patients were Regularly Followed up every 3 months for median observation 13.3 mo. In our study the prevalence of TNBC was %13.5 The average age of patients 49.5 years Their clinical and histopathological characteristics include: 90% Invasive Ductal carcinoma, 55.35% LN(Lymph node) pos. 61.3% P53 Pos, 74.5% Ki67 ³ 20, 68% grade III. There was No statistical differenced between control and treatment group in OS, DFS and PD median Followed up 13.3 mo. The results of study indicate that the adjuvant therapy with regimen CMF in TNBC patient after standard chemotherapy with Antracyline / Taxane- Base no affected out come in patient in Median follow up 13.3 mo.

Umbilical cord blood (UCB) as a source of hematopoetic Stem / Progenitor cells (HSPCs) used for umbilical cord blood transplantation (UCBT). The main obstacle in application of this source as an appropriate source of HSPCs is low volume of this product. So ex vivo expansion of these cells in a microenvironment which mimic body condition is important. In current study, we designed biocompatible microwells in which collagene type I is coated by softlitography method. Our findings designated that in 3-Dimensional (3D) microenvironment CD133+ UCB derived HSC expanded significantly compared to 2-Dimensional (2D) microenvironment.

Multiple Sclerosis is an inflammatory disease of the central nervous system in which T cells experienced a second phase of activation, which ultimately leads to axonal demyelination and neurological disability. Recent advancements in stem cell therapies may serve as potential treatments for neurological disorders. There are broad types of stem cells such as neural, embryonic, mesenchymal and hematopoietic stem cells with unprecedented hope in treating many debilitating diseases. In this paper we will review the substantial literature regarding experimental and clinical use of these stem cells and possible mechanisms in the treatment of MS. These results may pave the road for the utilization of stem cells for the treatment of MS.

Multiple myeloma is a malignant plasma cell disorder that accounts for approximately 10% of all hematologic cancers. It is characterized by accumulation of clonal plasma cells, predominantly in the bone marrow. The prevalence of type 2 diabetes is increasing; therefore, it is expected that there will be an increase in the diagnosis of multiple myeloma with concomitant diabetes mellitus. The treatment of multiple myeloma and diabetes mellitus is multifaceted. The coexistence of the two conditions in a patient forms a major challenge for physicians.

One of the complications of EBV (Epstein-BarrViruse) is HLH (hemophagocytic Lymphohistiocytosis). Although the patients who have developed HLH following EBV have normal immunity system, there are a few patients who are unmasked by EBV due to defect with their background immunity system, with no symptoms, shall develop HLH as well. Here is a brief summary of the case of a ten-year-old girl whose complications have been shown in form of neural disorders due to HLH caused by EBV. They have been prescribed Rituximab leading to weakening the inflammatory effect of EBV and the disease has subsided through quick treatment.